文献速递中医内科中药与中成药合理使用

黄连解毒汤干预中医「上火」证的机制研究

Huanglian Jiedu Decoction in the Treatment of the Traditional Chinese Medicine Syndrome "Shanghuo"-An Intervention Study.
PubMed 文献 · Front Pharmacol · 2021-04-30

该研究纳入57例「上火」所致口腔疾病患者和20名健康志愿者,分组观察黄连解毒汤(颗粒)干预前后炎症、氧化应激及能量代谢指标变化,并结合多组学分析潜在生物标志物。结果显示黄连解毒汤可显著降低琥珀酸、TNF-α、ATP、柠檬酸等指标,升高糖皮质激素、ACTH、乳酸、IL-4、IL-10等,差异代谢物与组氨酸、β-丙氨酸及鞘脂代谢相关,ATP与三羧酸循环调控可能在其疗效机制中起重要作用。

要点

  • 黄连解毒汤可降低「上火」口腔疾病患者琥珀酸、TNF-α、ATP、柠檬酸等指标。
  • 干预后糖皮质激素、ACTH、乳酸、IL-4、IL-10水平显著升高。
  • ATP与三羧酸循环调控可能是黄连解毒汤治疗「上火」的关键机制。

核心结论

  • 黄连解毒汤对「上火」所致口腔疾病具有干预作用,其机制可能与调控ATP及三羧酸循环相关。
  • 研究为揭示「上火」机制及寻找相关临床生物标志物奠定了基础。

研究设计与样本

  • 研究纳入57例「上火」所致口腔疾病患者和20名健康志愿者,分为口腔疾病组、黄连解毒汤干预组和健康对照组。
  • 检测干预前后炎症因子、氧化应激因子及能量代谢因子等生化指标,并采用多组学分析潜在生物标志物。

主要发现

  • 黄连解毒汤显著降低琥珀酸(p < 0.001)。
  • 黄连解毒汤显著降低肿瘤坏死因子-α、腺苷三磷酸、柠檬酸(p < 0.01)。
  • 黄连解毒汤显著降低白细胞介素-8、4-羟基壬烯醛、丙酮酸、乳酸脱氢酶(p < 0.05)。
  • 黄连解毒汤干预后糖皮质激素、促肾上腺皮质激素(p < 0.01)及乳酸、白细胞介素-4、白细胞介素-10(p < 0.05)显著升高。
  • 非靶向代谢组学显示7种差异代谢物在干预后接近健康对照组水平,靶向脂质组学鉴定出13种差异脂质。

关键数值与推荐

  • 非靶向代谢组学显示7种差异代谢物与组氨酸代谢、β-丙氨酸代谢和鞘脂代谢通路相关。
  • 靶向脂质组学及ROC曲线分析显示13种差异脂质主要集中于溶血磷脂酰胆碱和溶血磷脂酰乙醇胺。

临床怎么用

  • 黄连解毒汤可用于「上火」所致口腔疾病的干预,临床可结合炎症、氧化应激及能量代谢指标评估疗效。
  • ATP与三羧酸循环相关指标可能作为后续机制研究与临床生物标志物探索的方向。

局限性

  • 原文未报告样本量以外的设计细节、盲法及随访信息,机制结论仍需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

"Shanghuo" ("excessive internal heat") is caused by exuberant endogenous fire, which does not have a comprehensive and systematic traditional Chinese medicine theory. In previous study, we had evaluated the therapeutic effect of Huanglian Jiedu Decoction (HLJDD) (granule) on patients with "Shanghuo", however, the specific mechanism was not clear, which need further exploration. To explain its intervention mechanism, we select 57 patients with oral diseases caused by "Shanghuo" and 20 health volunteers to divide into oral disease group, HLJDD intervention group and healthy control group. Firstly, biochemical indicators before and after HLJDD intervention are detected, such as inflammatory factors, oxidative stress factors and energy metabolism factors. The results exhibit that HLJDD significantly decreases indicators succinic acid (p < 0.001); tumor necrosis factor-alpha, adenosine triphosphate, citric acid (p < 0.01); interleukin-8 (IL-8), 4-hydroxynonenal, pyruvic acid, lactate dehydrogenase (p < 0.05). The levels of glucocorticoid, adrenocorticotropic hormone (p < 0.01); lactic acid, IL-4, IL-10 (p < 0.05) significantly increase after HLJDD intervention. In addition, we adopt multi-omics analysis approach to investigate the potential biomarkers. Nontargeted metabolomics demonstrate that the levels of 7 differential metabolites approach that in the healthy control group after HLJDD intervention, which are correlated with histidine metabolism, beta-alanine metabolism and sphingolipid metabolism through metabolic pathway analysis. Targeted lipidomics results and receiver operating characteristic curve analysis show that 13 differential lipids are identified in the three groups mainly focuse on lysophosphatidylcholines, lysophosphatidylethanolamines. Finally, the network associations of those differential biomarkers reveal the regulation of adenosine triphosphate and tricarboxylic acid cycle play essential role in the therapeutic effect mechanism of HLJDD in "Shanghuo". The study has laid the foundation for further revealing the mechanism and finding clinical biomarkers related to "Shanghuo".

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Luo K, Zhao H, Bian B, et al. Huanglian Jiedu Decoction in the Treatment of the Traditional Chinese Medicine Syndrome "Shanghuo"-An Intervention Study. Front Pharmacol. 2021. PMID: 33995016. doi:10.3389/fphar.2021.616318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。